This study indicates that specifically targeting the activation of Keap1/Nrf2 signaling in pancreatic β-cells may be a useful pharmacological strategy for the clinical prevention and treatment of T1DM. The gene discussed is NFE2L2; the disease is type 1 diabetes mellitus.